NOV 09, 2017 1:30 PM PST

Importance of Measuring the Inhibition of Platelet Thromboxanes by Aspirin in Cardiovascular Disease Management and Prevention

Speaker
  • Medical Director, Corgenix Inc.
    Biography
      Luis R. Lopez, M.D., is the founder of Corgenix, Inc. (Broomfield, Colorado, USA) and currently serves as the Company's Medical Director. He received his MD degree in Lima, Peru, with Internal Medicine residency and postgraduate training in Clinical Immunology and Rheumatology at the University of Colorado Health Sciences Center in Denver Colorado. Dr. Lopez has worked in the field of immunodiagnostic of systemic autoimmune diseases including autoimmune-mediated atherothrombotic syndromes such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Recent work and publications have included serologic biomarkers to assess the risk of atherosclerotic cardiovascular diseases (CVD) such as oxidized low-density lipoprotein, ß2-Glycoprotein I and CRP complexes as well as pro-thrombotic platelet (urinary thromboxanes, 11dhTxB2) and inflammatory-derived F2-Isoprostanes metabolites.

    Abstract

    Antiplatelet therapy with aspirin (ASA) is widely used in cardiovascular disease (CVD) prevention because it inhibits platelet cyclooxygenase-1 (COX-1) and thromboxane A2 (TXA2)-mediated platelet aggregation, but not everyone fully benefit from ASA due to incomplete TXA2 suppression. Among the mechanisms to explain ASA failure (poor ASA response or ASA resistance), oxidative stress and inflammation have emerged as relevant factors. The relationship of urinary 11-dehydro-thromboxane B2 (11dhTxB2), an inactive stable metabolite of TxA2, and oxidative stress (urinary 8-isoPGF2α) in a cohort of stable coronary artery disease (CAD) patients on ASA treatment with the risk of adverse outcomes (mortality) was investigated. In this session, the effect of aspirin on platelet cyclooxygenase COX-1 and thromboxane (TxA2) inhibition, and its use in cardiovascular disease prevention will be reviewed. This review will include current laboratory measurement of urinary 11dhTxB2, a stable inactive metabolite of TxA2, to assess ASA response as a risk factor of CVD including mortality. Study results confirmed that laboratory measurement of urinary 11dhTxB2 represents a strong independent risk factor for all-cause mortality among stable CAD patients on ASA therapy. These results also indicate that 8-isoPGF2α and COX-2 thromboxane production not affected by ASA may maintain platelet hyperactivity irrespective of COX-1 inhibition. Poor ASA inhibition of 11dhTxB2 (ASA resistance) may prompt additional anti-oxidative and/or anti-inflammatory therapy in these patients aimed at modifying 5-year mortality risk.


    Show Resources
    You May Also Like
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    APR 20, 2021 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 20, 2021 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    APR 08, 2021 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 08, 2021 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 8, 2021 Time: 11:00am (PDT), 3:00pm (EDT) Pneumonia is a deadly condition with clinical outcomes highly dependent on prompt and appropriate therapy. Diagnosis of pneumonia is cha...
    DEC 09, 2020 9:00 AM PST
    C.E. CREDITS
    DEC 09, 2020 9:00 AM PST
    DATE: December 09, 2020 TIME: 09:00am PST Hematopoietic stem cells (HSCs) ensure homeostasis of blood throughout life. In this webinar, we share insights into the smart and easy isolation, c...
    NOV 09, 2017 1:30 PM PST

    Importance of Measuring the Inhibition of Platelet Thromboxanes by Aspirin in Cardiovascular Disease Management and Prevention


    No demographic data is available yet for this event.


    Show Resources
    Loading Comments...
    Show Resources